Pfizer, Merck Lose Appeal To Patent Cancer Drug Dosage
European officials have rejected Pfizer and Merck's second bid to patent a specific cancer drug dosage, ruling that the pharmaceutical giants didn't provide any new justification to protect the treatment they...To view the full article, register now.
Already a subscriber? Click here to view full article